Latest Conference

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

The ASCp meeting spotlights a fast-acting psychedelic for postpartum depression, vasopressin-targeting drugs, and ketamine’s promise for Parkinson symptoms.

Collaborative care boosts PTSD and opioid treatment together.

Study finds most bipolar depression outpatients have multiple comorbidities; many seek care, but substance use and phobias often go untreated.

Experts discuss ketamine safety, monitoring, neurotoxicity concerns, and key considerations for psychiatrists treating depression at the ASCP Annual Meeting.

APA session probes ADHD stimulant prescribing, contrasts population studies with RCTs, and explores education and brain effects.

Researchers at the ASCP Annual Meeting reported on how impaired brain insulin signaling may predict worsening depression severity and the links between metabolism and mood.

New trials find collaborative care improves OUD and mental health outcomes.

AI adoption in psychiatry and emerging psychedelic therapies are among the most anticipated topics at ASCP 2026, according to Benjamin Brody, MD.

John J. Miller, MD, Psychiatric Times editor in chief, looks forward to learning and sharing the late-breaking science, expert interviews, and new podcast conversations in psychopharmacology.

Psychiatrist Gus Alva highlights new depression therapies, neuromodulation, and why screening for bipolar disorder prevents antidepressant harm.

Learn why insomnia and daytime sleepiness signal psychiatric risk, and how screening for apnea, delayed phase, and fatigue sharpens treatment.

Explore why sexual health matters after 65 and how clinician comfort boosts disclosure.

Unpack gaming, gambling, social media, and exercise addiction, spotlighting comorbid anxiety, withdrawal signs, and harm-reduction treatment.

Learn how to spot bipolar mixed features, avoid antidepressant pitfalls, and choose evidence-based antipsychotics.

Digital gaming, gambling, and AI reliance drive emerging behavioral addictions, affecting mood and cognition.

Olanzapine-samidorphan keeps olanzapine efficacy yet limits weight gain, boosts negative symptoms, and cuts ER visits in real-world care.

Explore practical ways psychiatrists address sexual side effects and adjust medication for older adults.

How ketamine enhances psychotherapy—and what new psilocybin studies suggest about broader health effects.

Learn more about strategies for deprescribing, and the importance of finding the most effective medication possible.

See how overlooked birth trauma can mimic postpartum depression.

Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.

How psychiatric illness shapes cancer care and outcomes.

Learn more about medication use in pregnancy and postpartum, including risks and benefit analysis.

Learn why adult ADHD often hides behind anxiety or depression, how childhood history and family risk guide diagnosis, and why stimulants still matter.

Analysis of speech, acoustics, and facial cues reveals early psychosis and suicide risk.

MRI-guided SAINT TMS aims to remit treatment-resistant depression in days.